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Abstract
Background: Systems for identifying potentially inappropriate medications in older adults are not immediately
transferrable to advanced dementia, where the management goal is palliation. The aim of the systematic review
was to identify and synthesise published systems and make recommendations for identifying potentially
inappropriate prescribing in advanced dementia.
Methods: Studies were included if published in a peer-reviewed English language journal and concerned with
identifying the appropriateness or otherwise of medications in advanced dementia or dementia and palliative care.
The quality of each study was rated using the STrengthening the Reporting of OBservational studies in
Epidemiology (STROBE) checklist. Synthesis was narrative due to heterogeneity among designs and measures.
Medline (OVID), CINAHL, the Cochrane Database of Systematic Reviews (2005 – August 2014) and AMED were
searched in October 2014. Reference lists of relevant reviews and included articles were searched manually.
Results: Eight studies were included, all of which were scored a high quality using the STROBE checklist. Five
studies used the same system developed by the Palliative Excellence in Alzheimer Care Efforts (PEACE) Program. One
study used number of medications as an index, and two studies surveyed health professionals’ opinions on
appropriateness of specific medications in different clinical scenarios.
Conclusions: Future research is needed to develop and validate systems with clinical utility for improving safety
and quality of prescribing in advanced dementia. Systems should account for individual clinical context and
distinguish between deprescribing and initiation of medications.
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Background
Advanced dementia infers a range of physical and
psychosocial needs [1]. A palliative approach that
maximises comfort is considered best practice [2].
Medication use should be focused on symptom relief
and quality of life rather than treating secondary con-
ditions where burden is likely to outweigh clinical
benefit [2].
Most research on potentially inappropriate prescribing
has focused on the elderly rather than dementia specifically.
The harm/benefit risk ratios of numerous medications are
unfavourably affected by age-related changes in pharmaco-
kinetic and pharmacodynamic parameters [3]. Biological
changes can result in medications having longer durations
of action, greater risks of toxicity, and increased frequencies
of adverse effects.
Several systems for identifying potentially inappro-
priate medications in older adults have been devel-
oped to operationally define the harm/benefit risk in
clinical practice and research [4, 5]. These systems
have been applied in early but not advanced dementia
[6, 7]. Generalizability to people with advanced de-
mentia is limited by pathophysiological changes as de-
mentia progresses and the fact that systems have not
been developed for use where goals of care are pallia-
tive. In advanced dementia, there is an exaggerated
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decrease in total body water and muscle and an in-
crease in relative adipose tissue [8]. These changes
are additional to the changes due to aging and have a
direct and variable impact on the metabolism of
drugs [9]. This means that individuals with advanced
dementia may be more prone to adverse drug effects
and drug-drug interactions than other older people
[10]. People with advanced dementia are also less able
than others to report adverse effects or to be involved
in decision-making about whether to initiate or with-
draw medications. Finally, individuals with advanced
dementia have typically been excluded from research
examining quality use of medications in older popula-
tions, limiting evidence regarding benefits and harms.
Identifying potentially inappropriate medications to
guide prescribing practice for people with advanced
dementia is therefore likely to face challenges over
and above those for older populations more generally.
A review by Parsons et al. (2010) summarised literature
on specific medication types proposed to be potentially in-
appropriate for people with dementia nearing the end of
life, and examined decision-making regarding medication
discontinuation [9]. Potentially inappropriate medications
were identified to include anticholinesterase inhibitors,
memantine, antipsychotics, statins, antibacterials, antihy-
pertensives, antihyperglycaemic agents, anticoagulants
and medications to manage osteoporosis. Parsons et al.
highlighted the lack of guidance on identifying potentially
inappropriate medications and when and how to safely
discontinue medications at the end of life.
A distinct but related concept is polypharmacy. Poly-
pharmacy refers to the combination of multiple medica-
tions which may lead to cumulative adverse effects and
antagonistic drug-drug interactions where a worse ad-
verse effect is produced than either drug could have
caused alone [11]. Polypharmacy can lead to worse side
effects in the same domain (e.g. if receiving several psy-
choactive medications) or more side effects across differ-
ent domains (e.g. if receiving a psychoactive medication
and a blood pressure medication). Each of the medica-
tions involved may or may not be deemed potentially in-
appropriate on their own.
The current authors set out to update the review
by Parsons et al. using a more rigorous systematic
methodology and specifically aiming to identify and
synthesise any published systems and recommenda-
tions for identifying potentially inappropriate prescrib-
ing in people with advanced dementia.
Methods
This systematic review was undertaken in adherence
with the Preferred Reporting Items for Systematic
Reviews and Meta-analyses (PRISMA) Statement [12].
Eligibility criteria
Articles needed to be published in a peer-reviewed English
language journal and report on a system or recommenda-
tions for identifying the appropriateness or otherwise of
medications in advanced dementia or dementia and pallia-
tive care.
Information sources
Electronic databases Medline (OVID), CINAHL, the
Cochrane Database of Systematic Reviews (2005 – August
2014) and AMED were searched in October 2014. Refer-
ence lists of the review by Parsons et al. (2010) and
included articles were searched by hand.
Search
Database searches used keyword searches and medical
subject headings (MeSH) based on terms used by Parsons
et al. (2010) but further terms were also added as detailed
in Table 1.
Study selection
Two researchers (DD, TL) independently applied the eli-
gibility criteria to 10 % of search results and checked
inter-rater reliability. After finding 100 % agreement, a
single investigator (DD) rated the remaining 90 % arti-
cles alone. Full-texts were reviewed where a decision
could not be made on abstract and title alone.
Data collection and items
Data were extracted from eligible studies by a single re-
searcher (DD) using a standardised template. Data items
extracted included: study design, aims, setting, sample
size and characteristics, details of the approach taken to
Table 1 Electronic database search terms used to find articles
reporting on systems to identify potentially inappropriate
prescribing in people with advanced dementia
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αThe term “deprescribing” has been coined to describe the process of tapering or
withdrawing drugs with the goal of managing polypharmacy and improving
outcomes [31], *Truncation used to ensure all variations and different spelling of
words were retrieved
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identifying inappropriate medications, and outcome vari-
ables related to inappropriate prescribing.
Risk of bias in individual studies
The quality of each study was rated independently by
two researchers (DD and TL) using criteria from the
STrengthening the Reporting of OBservational studies in
Epidemiology (STROBE) [13]. Any disagreements were
resolved via discussion.
Synthesis
Expected heterogeneity among designs and methods
meant that synthesis needed to be narrative rather than
via meta-analysis. Methods for narrative synthesis were
based on techniques described by Popay et al. (2006) [14].
Results
Study selection
Database searches identified 882 records once duplicates
were removed. Five articles were included for analysis
from electronic database searches [15–19], and a further
three articles were additionally identified through hand
searching [20–22]. See Fig. 1 for more details.
Study characteristics
Characteristics of the eight studies included in this re-
view are summarised in Table 2. The studies variously
aimed to: 1) determine the prevalence of potentially in-
appropriate prescribing in aged care residents with
advanced dementia [15–18, 20, 22], 2) identify the fac-
tors associated with likelihood of potentially inappropri-
ate medications [16–18, 20, 22], and 3) explore the
perceptions of healthcare professionals regarding factors
determining medication-related decision-making in this
population [19, 21].
Five studies were undertaken in the USA [15–17, 19, 22]
and three were undertaken in European countries
[18, 20, 21].
Study designs included two cross-sectional surveys
[19, 21], three prospective cohort studies [15, 17, 18],
one of which reported the cross-sectional results of
medication data collected at baseline [18], two retro-
spective clinical record audits [20, 22], and one combin-
ing a retrospective clinical record audit with a consensus
panel component [16].
Six studies analysed medication data from a total of
7457 participants with advanced dementia, their age ran-
ging from 57 to 100 years of age and the majority being
female, ranging from 55.2 % [15] to 87.5 % [17] of their
samples. Of these, four studies focused solely on nursing
homes [15–17, 20, 22] while two also included people
with advanced dementia receiving home care [18, 20].
Risk of bias within studies
The eight studies included in the systematic review were
generally of high quality as rated by STROBE criteria,
complying with 76 % [16] to 100 % [17, 22] of criteria.
However, Toscani et al. (2013) did not indicate the
Fig. 1 Flowchart depicting inclusion/exclusion
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Inappropriate drug use in 643
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commonly prescribed inappropriate
drugs were lipid-lowering agents
(9.9 %), antiplatelet agents (9.9 %),
Ach inhibitors (7.2 %) and anti-
spasmodics (6.9 %). Inappropriate
drug use associated with diabetes,
HF, stroke, recent hospitalization.
An inverse relationship between
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medications per resident.
53.9 % of residents receiving at least
one medication with questionable
benefit. Anticholinesterase inhibitors
(36.4 %), memantine (25.2 %) and
lipid-lowering agents (22.4 %) most
commonly prescribed medications
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reported that at least 20 % of
patients were taking
anticholinesterase inhibitor or
memantine at hospice admission.
80 % of respondents would
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agents, however, a subset believe
they stabilize cognition (22 %),
decrease challenging behaviours
(28 %), maintain patient function
(22 %,) reduce caregiver burden
(20 %) and improve caregiver quality
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study’s design in the title or abstract [18], and Colloca et
al. (2012) did not sufficiently explain a larger study’s de-
sign from which their data were drawn [20]. Four studies
did not give a rationale for sample size [15, 16, 20, 21].
Three studies did not attempt to address potential sources
of bias [15, 16, 21]. These same three studies also provided
limited descriptions of statistical methods or how they dealt
with missing data. Three studies did not provide unadjusted
results for their multivariate analyses [16, 18, 20], and one
controlled only for gender and age rather than other socio-
demographic, clinical and nursing home variables [18].
Two studies did not discuss the generalizability of their re-
sults [18, 19].
Synthesis of results
Five of the eight studies [16–18, 20, 22] used the same sys-
tem for identifying potentially inappropriate medications
– that was developed by the Palliative Excellence in Alz-
heimer Care Efforts (PEACE) Program reported by Holmes
et al. (2008) [16]. In the PEACE program, medications
were audited for 34 patients with advanced dementia
where a palliative approach was deemed appropriate. In a
three-round modified Delphi process, 12 geriatricians
rated each medication identified via the audit as ‘never’,
‘rarely’, ‘sometimes’ or ‘always’ appropriate. Consensus for
a medication or medication class was defined as agree-
ment on categorisation by >50 % (i.e. at least 7/12) partici-
pants. See Table 3 for drug classes in each category
according to the final consensus.
Following Holmes and colleagues’ preliminary study [16],
four other international studies utilised [17, 18, 20, 22] the
PEACE criteria to rate the appropriateness of medications
taken by large cohorts of aged care residents with advanced
dementia and examine predictors of taking ‘never’ appro-
priate medications among socio-demographic and clinical
variables. See Table 4 for a summary of these studies’ sam-
ples and results.
Blass et al. (2008) used a more rudimentary index of po-
tentially inappropriate prescribing in people with ad-
vanced dementia based purely on number of medications
[15]. The study identified that nursing home residents
with advanced dementia received a mean of 14.6 medica-
tions (±7.4) and that, as residents approached death, the
type but not number of medications altered. The study
identified an increase in medications for symptom control
(i.e. opioids and laxatives) and a decrease in medications
for comorbid conditions (i.e. antibiotics, anti-dementia
drugs, cardiovascular agents and psychotropic agents).
Two studies by Shega et al. (2009) and Parsons et al.
(2014) explored factors influencing medication-related
decisions by physicians (hospital medical directors [19],
general practitioners and hospital physians [21]), specif-
ically their continuation or discontinuation in dying pa-
tients with dementia [19, 21]. Physicians from both
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Sourced from Holmes et al. (2008) [16]
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Table 4 Results from studies utilising PEACE criteria to determine appropriateness of medications in individuals with advanced dementia
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Tjia et al.
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aas defined by the Palliative Excellence in Alzheimer Care Efforts (PEACE) criteria reported by Holmes et al. (2008) [13]
bLess than 1 year in nursing home
cBedford Alzheimer Nursing Scale – Severity Subscale, possible range 7–28, higher scores indicate greater functional disability
dpossible range 0–24, lower scores indicate greater cognitive impairment
eCardiovascular disease includes history of coronary artery disease and cerebrovascular accident
fAcute illnesses include infectious episodes myocardial infarction, stroke, any bone fracture, gastrointestinal bleed, and seizure
gany hospitalization occurring in the last 90 days
hADL hierarchical scale score ranges from 0 (no impairment) to 6 (total dependence in self-care)













studies recommended discontinuation of anticholinester-
ase inhibitors and memantine because of perceived lack
of clinical benefit during end-stage of illness [21], but
were less likely to recommend this if there was any indi-
cation that they stabilised cognition, reduced challenging
behaviours or maintained patient function [19]. Physi-
cians also recommended discontinuing quetiapine and
simvastatin because of a perceived lack of indication
and/or risk of adverse effects such as confusion [21].
Emphasis was placed on ensuring patient comfort and
symptom management and reducing polypharmacy and
preventative treatments.
Discussion
This systematic review identified only one system for
identifying potentially inappropriate medications in
people with advanced dementia that had any degree of
validation – the PEACE criteria developed by Holmes et
al. (2008) [16]. A second system we identified relied on
number of medications alone [15]. Finally, two other
studies have sought to understand the decision-making
process of health professionals when determining the
appropriateness of medications in end-stage dementia.
Whilst providing a useful foundation, the PEACE criteria
are limited in a number of ways. Holmes et al. (2008)
themselves identified a need for further validation of the
system by means of a larger sample of medication data and
a more representative expert panel of health professionals.
Their expert informants were all geriatricians from the
University of Chicago. Moreover, Holmes et al. (2008) did
not report informants’ rationale for medication classifica-
tion within the system. Authors using the PEACE criteria
since have highlighted its ‘one size fits all’ approach and
the importance of taking into account each older individ-
ual’s life expectancy [17, 18, 20], comorbidities, symptom
experience [16, 22] and goals of care [18]. These concerns
are especially applicable to the PEACE categories of ‘some-
times’ and ‘rarely’ appropriate, which are of limited useful-
ness without a better understanding of factors influencing
decision-making.
Studies using the PEACE criteria suggest insights into
how this system might be refined and validated in the
future. Percentages of residents ‘never’ appropriate medi-
cations varied between studies. In addition to differences
in prescribing cultures between countries and organisa-
tions included in these studies, differences in rates of
never appropriate medications may have resulted in part
from variability in the methods used to define advanced
dementia and code medications. Three studies used the
Cognitive Performance Scale (CPS) [17, 20, 22] to define
advanced dementia while two others used the Functional
Assessment Staging Tool (FAST) [16, 18]. With regard
to coding medications, two studies used the Anatomical
Therapeutic Classification (ATC) System [18, 20] and
two used the British National Formulary [17, 22]; both
these approaches differed from the original study, which
utilised the British National Formulary, United States
Pharmacopeia and National Formulary and the Lexi-
Comp alphabetical drug index [16]. While Colloca et al.
did not provide a list of ATC codes they included, Tos-
cani et al. indicated that ATC codes (beginning with
N06DA) for anti-dementia drugs (rivastigmine, donepe-
zil and galantamine) were allocated to “central nervous
system stimulants” thereby placing these medications
under the PEACE category ‘no consensus.’ However Colloca
et al. may have allocated the same ATC codes to “acetyl-
cholinesterase inhibitors,” placing them under the PEACE
category ‘never appropriate,’ and may explain the difference
in proportions of residents receiving never appropriate med-
ications between studies. However, despite such differences
between inclusion criteria and methods, findings from
studies using the PEACE criteria have in some cases been
surprisingly consistent with three studies reporting the
most commonly prescribed ‘never’ appropriate medica-
tions as anticholinesterase inhibitors and lipid-lowering
agents [17, 20, 22].
The authors of several studies in our review inter-
preted their results as indicating that people with ad-
vanced dementia undergo excessive pharmacological
treatment [15, 16, 20, 22]. The reasons speculated in-
cluded a lack of evidence-based guidance for clinicians
[15, 20–22], a hesitancy among health professionals to
take patients off medications where the impact has not
been formally evaluated in advanced dementia [15, 19, 21],
and the possibility that prescribers may not have recognised
advanced dementia as a terminal illness needing to be
treated with a palliative approach [18]. It may also be that
discussions about reducing medications are sometimes
avoided by health professionals because they require ac-
knowledgement that the person with dementia is nearing
the end of life [23]. This particular challenge has been iden-
tified in other palliative populations across a range of set-
tings. Collier et al. (2013) have created a model to provide a
systematic framework for hospice clinicians to have difficult
conversations with patients, families and interdisciplinary
clinical colleagues about the need to change prescribing
when clinical decline occurs [23]. While broadly developed
for individuals receiving end of life care, it may be applied
to individuals with advanced dementia in order to facilitate
discussion and improve care.
The widely held view that polypharmacy is undesir-
able in advanced dementia and end of life care is
consistent with evidence that number of medications
is related to adverse outcomes such as delirium, cog-
nitive decline and loss of appetite [24]. However,
when used in isolation (as by Blass et al. [2008] [15]),
number of medications is too simplistic to be a useful
index of the safety and quality of prescribing in
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advanced dementia. Both Blass et al. themselves and
Tjia et al. found that the type but not number of
medications changed over time as individuals with ad-
vanced dementia approached death, and a cross-
sectional study has found that patients taking fewer
than eight medications were more likely to be under-
using a potentially useful medication [25]. The aim of
palliative prescribing is to support comfort and qual-
ity of life, and in many cases, medications may need
to be added to mitigate symptoms [23].
Reducing numbers of medications at the end of life
also requires due attention to complexities inherent in
deprescribing. While medications can be withdrawn
safely, there is a risk of withdrawal reactions, symptom
recurrence or reactivation of underlying disease [26].
Evidence is lacking in advanced dementia, however there
is a growing body of research on the potential benefits
of deprescribing in older people more generally [26]. It
was shown that medication classes for secondary pre-
vention such as lipid-lowering agents, antibiotics, antihy-
pertensives and psychotropics can be withdrawn in older
patients without causing harm. A system has been devel-
oped to inform deprescribing in disabled older adults in
the form of an algorithm for decision-making [27]. Drug
discontinuation based on this algorithm has been found
not to increase significant adverse events, and only 10 %
of the drugs ceased had to be readministered because of
the return of the original indication for the drug. The
same authors also tested their deprescribing algorithm
in older adult community dwellers and were able to suc-
cessfully deprescribe medications in 81 % of their sample
with no significant adverse events or deaths attributable
to discontinuation [28]. Future work is needed to exam-
ine the applicability of this algorithm to people with ad-
vanced dementia specifically and adapt as necessary.
First and foremost, this review is limited by the
small pool of studies found that have focused on
identifying potentially inappropriate medications in
people with advanced dementia, limiting the avenues
available for synthesis and conclusion. In particular,
the absence of any studies validating systems against
clinical outcomes necessarily limits the evidence base
for improving the safety and quality of medication
use in advanced dementia. Methodological limitations
of the review include not requiring the primary aim
of included studies to match those of this review and
the possibility that we may not have identified all
relevant research in the field. Whilst we expanded the
search terms used by a previous review [9] and took
a systematic approach to inclusion/exclusion, articles
in the field of deprescribing are notoriously difficult
to find [29], and nearly half the articles included in
this study were found through hand searching rather
than through databases.
Conclusion
While there are well-accepted criteria available for iden-
tifying potentially inappropriate prescribing in older
adults, these cannot be readily applied to the case of ad-
vanced dementia, where there are disease-specific con-
cerns and a palliative approach is needed. The PEACE
criteria show promise for further development, but re-
quire further studies to elucidate how decision-making
should be informed by individual clinical context and
how considerations may differ between deprescribing
versus initiation. Further studies are also needed to iden-
tify potentially inappropriate medications with reference
to empirical data on adverse events and other negative
outcomes, rather than solely relying on the perceptions
of health professionals and data and theory relating to
standard pharmacological theory. Finally, studies are
needed to test the ability of systems to identify poten-
tially inappropriate prescribing to improve the quality
and safety of medication use in people with advanced
dementia.
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